Free Account Opening + AMC Free Demat
Loading...

Ajanta Pharma Buyback 2023 vs Natco Pharma Buyback 2023

Comparision between Ajanta Pharma Buyback 2023 and Natco Pharma Buyback 2023.

Buyback Details

Ajanta Pharma Buyback 2023 is a Tender Offer buyback proposed to list at BSE, NSE while Natco Pharma Buyback 2023 is a Open Market Through Stock Exchange proposed to list at BSE, NSE.

  Ajanta Pharma Limited Natco Pharma Limited
Logo Ajanta Pharma Buyback 2023 Logo Natco Pharma Buyback 2023 Logo
Type of Buyback Tender Offer Open Market Through Stock Exchange
Listing At BSE, NSE BSE, NSE
Face Value ₹2 per share ₹2 per share
Buyback Price ₹1425 per share ₹700 per share
Issue Size 22,10,500 shares
Issue Size (Amount) ₹315.00 Crores ₹210.00 Crores
Buyback Ratio
CategoryEntitlement Ratio of BuybackShares Offered
Reserved Category for Small Shareholders20 Equity Shares out of every 99 Fully paid-up Equity Shares held on the Record Date.331,575.00
General Category for all other Eligible Shareholders3 Equity Shares out of every 202 Fully paid-up Equity Shares held on the Record Date.1,878,925.00
Registrar Link Intime India Private Ltd Venture Capital And Corporate Investments Pvt Ltd
Lead Managers Edelweiss Financial Services Ltd Dam Capital Advisors Ltd (Formerly Idfc Securities Ltd)
Necessity of the buyback

The buyback is being undertaken for the following reasons:

  1. The buyback will help the company to return surplus cash to its equity shareholders broadly in proportion to their shareholding, thereby enhancing the overall return to shareholders.
  2. The buyback consists of a reservation for the small shareholder. The company believes that this reservation for small shareholders would benefit a large number of public shareholders who would get classified as "small shareholders".
  3. The buyback may help in improving return on equity, reduction in the equity base, thereby leading to a long-term increase in shareholders' value.
  4. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer.
  5. The buyback may lead to a reduction in outstanding Equity Shares, an improvement in earnings per equity share, and an enhanced return on equity.

The Buyback is being undertaken for the following reasons:

  1. The Buyback will help the Company to return surplus cash to its shareholders holding Equity Shares
  2. The Buyback may help in improving return on equity, by the reduction in the equity base.
  3. The Buyback gives an option to the shareholders holding Equity Shares of the Company, who can choose to participate and get cash in lieu of Equity Shares or they may choose not to participate and enjoy a resultant increase in their percentage shareholding, post the Buyback offer.

Buyback Timetable

Ajanta Pharma Buyback 2023 and Natco Pharma Buyback 2023 buyback timetable. The investors should have the company's shares in their demat accounts as of the record date. Ajanta Pharma Buyback 2023 Buyback record date is Mar 24, 2023. Natco Pharma Buyback 2023 Buyback record date is .

  Ajanta Pharma Limited Natco Pharma Limited
Record Date Mar 24, 2023
Offer Open Date Mar 31, 2023 Mar 21, 2023
Offer Closure Date Apr 10, 2023 May 12, 2023
Last date for receipt of tender forms Apr 10, 2023
Finalisation of buyback Apr 13, 2023
Last Date for settlment of bids Apr 18, 2023
Last Date for extinguishment of shares Apr 27, 2023

Financial Details and Other Relevent Information

Comparison of Ajanta Pharma Buyback 2023 and Natco Pharma Buyback 2023 financial data. The table below also includes a list of all relevant information like Stock Market Data, Compay Information, Lead Manager and Registrar.

  Ajanta Pharma Limited Natco Pharma Limited
Financial
Ajanta Pharma Limited Financial Information (Restated Consolidated)
Period EndedTotal AssetsTotal RevenueProfit After Tax
31-Mar-202,680.06467.70
31-Mar-213,778.722,915.67653.87
31-Mar-224,055.583,456.67712.68
Amount in ₹ Crore
Natco Pharma Limited Financial Information (Restated Consolidated)
Period EndedTotal RevenueProfit After TaxNet Worth
31-Mar-202,022.40458.103,773.50
31-Mar-212,155.70442.404,121.60
31-Mar-222,043.80170.004,263.60
31-Dec-221,884.80439.504,628.20
Amount in ₹ Crore
Stock price at BSE

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Feb-2023 1252.00 4523.00 1197.49
Jan-2023 1222.90 3168.00 1186.12
Dec-2022 1272.00 1192.00 1210.90

Stock price at BSE (in preceding 3 months)

Month High Price Low Price Average Price
Feb-2023 554.95 502.00 535.04
Jan-2023 570.40 526.00 545.28
Dec-2022 599.00 548.00 565.78
Stock price at NSE

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Feb-2023 1254.00 1151.35 1198.12
Jan-2023 1224.00 1150.00 1186.49
Dec-2022 1266.25 1150.25 1210.19

Stock price at NSE (in preceding 3 months)

Month High Price Low Price Average Price
Feb-2023 555.00 502.00 534.88
Jan-2023 570.00 526.10 545.36
Dec-2022 600.00 547.50 565.78

Comments

Add a public comment...